Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.72 |
| ▸ | CX3CR1 | P49238 | 4/20 | 0.70 |
| ▸ | CCR7 | P32248 | 2/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842874 | 0.91 | CXCR2 (0.68) | CXCR2CX3CR1CCR7HTR1BCXCR1 | |
| SCHEMBL842857 | 0.91 | CXCR2 (0.66) | CXCR2CX3CR1CCR7HTR1BCXCR1 | |
| SCHEMBL16543236 | 0.90 | CXCR2 (0.73) | CXCR2CX3CR1CCR7HTR1B | |
| SCHEMBL5036023 | 0.86 | CXCR2 (0.70) | CXCR2CX3CR1CCR7HTR1B | |
| SCHEMBL840891 | 0.86 | CXCR2 (0.64) | CXCR2CX3CR1CCR7HTR1BCXCR1 | |
| SCHEMBL842524 | 0.85 | CXCR2 (0.86) | CXCR2CX3CR1HTR1B | |
| SCHEMBL841849 | 0.85 | CXCR2 (0.81) | CXCR2CX3CR1HTR1B | |
| SCHEMBL842340 | 0.84 | CXCR2 (0.71) | CXCR2CX3CR1CCR7HTR1BCXCR1 | |
| SCHEMBL841899 | 0.84 | CXCR2 (1.00) | CXCR2CX3CR1HTR1B | |
| SCHEMBL2905264 | 0.84 | CXCR2 (0.71) | CXCR2CX3CR1CCR7HTR1BCXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348709-B1 | Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis | ASTRAZENECA UK LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | claimed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | claimed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | claimed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | claimed |
| US-8143261-B2 | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED | 2009-11-12 | — | — | US | disclosed |
| EP-1348709-B1 | Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis | ASTRAZENECA UK LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
| EP-1222195-A1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025242-A1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | TYMS, DPYD, TYMP | CXCR2 378/4885CX3CR1 2551/4885CCR7 2446/4885 |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | TYMS, DPYD, TPMT | CXCR2 195/4885CX3CR1 2122/4885CCR7 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.